Bayer Consumer Group 70% Growth Driven By Roche OTC Buy
This article was originally published in The Tan Sheet
Executive Summary
Bayer posted "exceptionally strong" third-quarter gains in its consumer care division with sales increasing 70% to $695.1 mil. (€1 = $1.18), primarily due to products newly acquired in the Roche purchase
You may also be interested in...
Avoiding GMP “Showstoppers” Keeps Manufacturers Off FDA’s “Radar”
Compliance consultants warn that certain dietary supplement good manufacturing practices violations are inspection "showstoppers" and will draw agency enforcement
Avoiding GMP “Showstoppers” Keeps Manufacturers Off FDA’s “Radar”
Compliance consultants warn that certain dietary supplement good manufacturing practices violations are inspection "showstoppers" and will draw agency enforcement
Chattem’s Financing Strategy Keeps Door Open For Acquisitions
Chattem remains in the hunt for acquisitions because its preferred financing strategy continues to be attractive even with lending activity slowed worldwide, according to President and Chief Operating Officer Bob Bosworth